Target- |
Mechanism- |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 2 肝力保胶囊治疗慢性乙型肝炎有效性和安全性的随机双盲、安慰剂平行对照、加载试验、多中心临床研究
[Translation] A randomized, double-blind, placebo-controlled, loading trial, multicenter clinical study on the efficacy and safety of Ganlibao capsule in the treatment of chronic hepatitis B
1.探索肝力保胶囊治疗慢性乙型肝炎(湿热脾虚证)的抗炎保肝作用和抗病毒作用。2.探索肝力保胶囊对于慢性乙型肝炎的证候改善作用。3.观察肝力保胶囊临床应用的安全性。
[Translation] 1. To explore the anti-inflammatory, hepatoprotective and antiviral effects of Ganlibao Capsule in the treatment of chronic hepatitis B (damp-heat spleen deficiency syndrome). 2. To explore the symptom-improving effect of Ganlibao Capsule on chronic hepatitis B. 3. To observe the safety of Ganlibao Capsule in clinical application.
安慰剂对照评价肝力保胶囊治疗慢性乙型肝炎湿热脾虚证有效性和安全性随机双盲、平行对照、多中心临床研究
[Translation] A placebo-controlled, double-blind, parallel-controlled, multicenter clinical study to evaluate the efficacy and safety of Ganlibao capsules in the treatment of chronic hepatitis B with damp-heat and spleen deficiency syndrome
初步评价肝力保胶囊治疗的慢性乙型肝炎湿热脾虚证有效性和安全性。
[Translation] To preliminarily evaluate the efficacy and safety of Ganlibao Capsule in the treatment of chronic hepatitis B with damp-heat and spleen deficiency syndrome.
100 Clinical Results associated with Shanghai Hufeng Biotechnology Co., Ltd.
0 Patents (Medical) associated with Shanghai Hufeng Biotechnology Co., Ltd.
100 Deals associated with Shanghai Hufeng Biotechnology Co., Ltd.
100 Translational Medicine associated with Shanghai Hufeng Biotechnology Co., Ltd.